| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2026年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
2025年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
2024年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
2023年度: 1,170千円 (直接経費: 900千円、間接経費: 270千円)
|
|---|
| 研究実績の概要 |
We examined the fibrosis in a mouse model of pancreatic cancer (PDAC mouse model) and the effect of treatments on these fibrotic tumors. PDAC mouse model was established by inoculating C57 BL/6J mice with PAN02 cell line (NCI, Frederick), and analyzed the fibrosis as well as the immune status of the host using immunohistochemistry (IHC). Tumor tissue of PDAC mouse model characterized by increased fibrotic component, confirmed by AZAN, Anti-Collagen I and Anti-Collagen IV staining. Regarding the immune response in tumor microenvironment, we observed the infiltration of immune-mediating cells including CD8a+, CD4+, and CD11b+ cells and myeloid-lineage inflammatory cells including F4/80+, Ly-6C+, Ly-6G+, CD86+, CD206+ cells in tumor tissue of these mice.
Next, we explored the effect of treatments on fibrosis and host immune system. We confirmed administration of Gemcitabine, a first-line anticancer drug, and immunotherapy reduced the fibrosis in these tumors. In addition, we observed a substantial increase in the infiltration of CD11b+, F4/80+, CD8a+, CD4+ cells into tumors of treated mice.
The current experiments provide a preclinical study suited to evaluate the efficacy of drugs targeting the tumor stroma.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
Basic research examines the fibrosis in microenvironment of pancreatic cancer. Preliminary studies have been conducted, a mouse model with fibrotic tumor has been established, and the procedure has been established in other past studies, so we believe that the overall project is progressing rather smoothly.
|
